Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson sold 4,077 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $127,895.49. Following the sale, the chief operating officer now owns 166,578 shares of the company’s stock, valued at $5,225,551.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
John Nicholson also recently made the following trade(s):
- On Tuesday, February 19th, John Nicholson sold 3,822 shares of Nektar Therapeutics stock. The stock was sold at an average price of $42.39, for a total transaction of $162,014.58.
NASDAQ NKTR traded up $0.68 on Friday, hitting $32.02. 1,480,671 shares of the company were exchanged, compared to its average volume of 1,752,666. The firm has a market cap of $5.91 billion, a PE ratio of 8.47 and a beta of 2.96. Nektar Therapeutics has a 12 month low of $29.22 and a 12 month high of $92.17. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.03. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. The firm had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. During the same period last year, the firm earned ($0.60) earnings per share. On average, equities analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. lifted its stake in shares of Nektar Therapeutics by 150.2% in the first quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 479 shares in the last quarter. Quantamental Technologies LLC bought a new position in shares of Nektar Therapeutics in the first quarter valued at $27,000. CSat Investment Advisory L.P. lifted its stake in shares of Nektar Therapeutics by 279.2% in the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at $39,000. Finally, Sandy Spring Bank bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at $59,000. 94.90% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages recently issued reports on NKTR. ValuEngine lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 31st. Svb Leerink began coverage on shares of Nektar Therapeutics in a research note on Friday, March 15th. They set a “mkt perform” rating and a $38.00 target price on the stock. BMO Capital Markets began coverage on shares of Nektar Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $75.00 target price on the stock. Zacks Investment Research lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, TheStreet raised shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a research note on Thursday, February 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. Nektar Therapeutics has a consensus rating of “Buy” and an average target price of $69.73.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2019/05/17/insider-selling-nektar-therapeutics-nktr-coo-sells-4077-shares-of-stock.html.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.